Gene targeting of components of the fibrinolytic system

被引:18
作者
Ploplis, VA
Castellino, FJ
机构
[1] Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA
[2] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA
关键词
gene deficiencies; fibrinolysis; hemostasis; blood;
D O I
10.1055/s-0037-1612938
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A number of in vitro and in vivo observations have implicated components of the fibrinolytic system in events associated with diverse processes physiological and pathophysiological processes, ranging from embryo implantation to cancer. Advances in gene targeting technology have led to the generation of mice deficient for components of the fibrinolytic system. Remarkably, these animals survive to adulthood with few spontaneous life threatening events. Thus, these mice are valuable resources for in vivo studies, not only for hemostasis-related research, but also for the relationships of these genes to other disease states associated with cellular growth and mobility, along with angiogenesis, vascular remodeling, inflammation, wound healing, and tumor growth and dissemination.
引用
收藏
页码:22 / 31
页数:10
相关论文
共 108 条
[1]   Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury [J].
Akassoglou, K ;
Kombrinck, KW ;
Degen, JL ;
Strickland, S .
JOURNAL OF CELL BIOLOGY, 2000, 149 (05) :1157-1166
[2]   The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin:: Implications for antiangiogenic strategies [J].
Bajou, K ;
Masson, V ;
Gerard, RD ;
Schmitt, PM ;
Albert, V ;
Praus, M ;
Lund, LR ;
Frandsen, TL ;
Brunner, N ;
Dano, K ;
Fusenig, NE ;
Weidle, U ;
Carmeliet, G ;
Loskutoff, D ;
Collen, D ;
Carmeliet, P ;
Foidart, JM ;
Noël, AS .
JOURNAL OF CELL BIOLOGY, 2001, 152 (04) :777-784
[3]   Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization [J].
Bajou, K ;
Noël, A ;
Gerard, RD ;
Masson, V ;
Brunner, N ;
Holst-Hansen, C ;
Skobe, M ;
Fusenig, NE ;
Carmeliet, P ;
Collen, D ;
Foidart, JM .
NATURE MEDICINE, 1998, 4 (08) :923-928
[4]   Urokinase-type plasminogen activator in inflammatory cell recruitment and host defense against Pneumocystis carinii in mice [J].
Beck, JM ;
Preston, AM ;
Gyetko, MR .
INFECTION AND IMMUNITY, 1999, 67 (02) :879-884
[5]   Plasminogen deficiency leads to impaired remodeling after a toxic injury to the liver [J].
Bezerra, JA ;
Bugge, TH ;
Melin-Aldana, H ;
Sabla, G ;
Kombrinck, KW ;
Witte, DP ;
Degen, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) :15143-15148
[6]   Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator [J].
Bugge, TH ;
Flick, MJ ;
Danton, MJS ;
Daugherty, CC ;
Romer, J ;
Dano, K ;
Carmeliet, P ;
Collen, D ;
Degen, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (12) :5899-5904
[7]  
Bugge TH, 1997, BLOOD, V90, P4522
[8]   Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice [J].
Bugge, TH ;
Lund, LR ;
Kombrinck, KK ;
Nielsen, BS ;
Holmbäck, K ;
Drew, AF ;
Flick, MJ ;
Witte, DP ;
Dano, K ;
Degen, JL .
ONCOGENE, 1998, 16 (24) :3097-3104
[9]   THE RECEPTOR FOR UROKINASE-TYPE PLASMINOGEN-ACTIVATOR IS NOT ESSENTIAL FOR MOUSE DEVELOPMENT OR FERTILITY [J].
BUGGE, TH ;
SUH, TT ;
FLICK, MJ ;
DAUGHERTY, CC ;
ROMER, J ;
SOLBERG, H ;
ELLIS, V ;
DANO, K ;
DEGEN, JL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (28) :16886-16894
[10]   PLASMINOGEN DEFICIENCY CAUSES SEVERE THROMBOSIS BUT IS COMPATIBLE WITH DEVELOPMENT AND REPRODUCTION [J].
BUGGE, TH ;
FLICK, MJ ;
DAUGHERTY, CC ;
DEGEN, JL .
GENES & DEVELOPMENT, 1995, 9 (07) :794-807